David Shaw’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $299K | Buy |
115,462
+70,606
| +157% | +$209K | ﹤0.01% | 4414 |
|
|
2026
Q1 | $138K | Buy |
+44,856
| New | +$194K | ﹤0.01% | 4251 |
|
|
2025
Q1 | – | Sell |
-105,130
| Closed | -$1.13M | – | 4243 |
|
|
2024
Q4 | $1.13M | Buy |
+105,130
| New | +$809K | ﹤0.01% | 3133 |
|
|
2024
Q3 | – | Sell |
-58,355
| Closed | -$246K | – | 4526 |
|
|
2024
Q2 | $246K | Sell |
58,355
-11,263
| -16% | -$45.6K | ﹤0.01% | 3991 |
|
|
2024
Q1 | $354K | Buy |
69,618
+16,164
| +30% | +$91K | ﹤0.01% | 3651 |
|
|
2023
Q4 | $498K | Buy |
53,454
+20,913
| +64% | +$144K | ﹤0.01% | 3515 |
|
|
2023
Q3 | $213K | Sell |
32,541
-12,563
| -28% | -$100K | ﹤0.01% | 3737 |
|
|
2023
Q2 | $367K | Buy |
+45,104
| New | +$387K | ﹤0.01% | 3536 |
|
|
2023
Q1 | – | Sell |
-46,190
| Closed | -$428K | – | 4423 |
|
|
2022
Q4 | $428K | Sell |
46,190
-257,959
| -85% | -$2.76M | ﹤0.01% | 3939 |
|
|
2022
Q3 | $3.14M | Sell |
304,149
-73,205
| -19% | -$773K | ﹤0.01% | 2593 |
|
|
2022
Q2 | $3.78M | Buy |
377,354
+67,962
| +22% | +$644K | ﹤0.01% | 2474 |
|
|
2022
Q1 | $3.81M | Buy |
309,392
+292,864
| +1,772% | +$3.6M | ﹤0.01% | 2636 |
|
|
2021
Q4 | $287K | Sell |
16,528
-28,351
| -63% | -$539K | ﹤0.01% | 4697 |
|
|
2021
Q3 | $806K | Sell |
44,879
-54,814
| -55% | -$1.09M | ﹤0.01% | 3772 |
|
|
2021
Q2 | $2.28M | Buy |
99,693
+48,244
| +94% | +$715K | ﹤0.01% | 2811 |
|
|
2021
Q1 | $769K | Buy |
+51,449
| New | +$562K | ﹤0.01% | 3288 |
|
|
2020
Q3 | – | Sell |
-31,195
| Closed | -$153K | – | 3823 |
|
|
2020
Q2 | $153K | Sell |
31,195
-29,563
| -49% | -$112K | ﹤0.01% | 3835 |
|
|
2020
Q1 | $191K | Sell |
60,758
-10,792
| -15% | -$37.6K | ﹤0.01% | 3659 |
|
|
2019
Q4 | $185K | Buy |
+71,550
| New | +$188K | ﹤0.01% | 3817 |
|
|
2019
Q3 | – | Sell |
-35,587
| Closed | -$120K | – | 3800 |
|
|
2019
Q2 | $120K | Buy |
+35,587
| New | +$111K | ﹤0.01% | 3533 |
|
|
2018
Q1 | – | Sell |
-16,140
| Closed | -$52K | – | 3478 |
|
|
2017
Q4 | $52K | Buy |
+16,140
| New | +$63.5K | ﹤0.01% | 3532 |
|
|
2016
Q4 | – | Sell |
-119,534
| Closed | -$434K | – | 3421 |
|
|
2016
Q3 | $434K | Buy |
119,534
+105,080
| +727% | +$442K | ﹤0.01% | 2866 |
|
|
2016
Q2 | $88K | Buy |
+14,454
| New | +$69.8K | ﹤0.01% | 3266 |
|
Other funds holding AVXL
SF
David Shaw's AVXL Position: Q2 2026 in Review
David Shaw increased its Anavex Life Sciences (AVXL) stake by 157% in Q2 2026, buying an estimated $209K and bringing the position to 115,462 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #4414.
David Shaw first reported a position in AVXL in Q2 2016 and has held it in 23 quarters since. The position peaked at $3.81M in Q1 2022. 177 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.
- David Shaw held 115,462 shares of Anavex Life Sciences worth $299K as of Q2 2026.
- David Shaw bought 70,606 Anavex Life Sciences shares in Q2 2026, an estimated $209K.
- Anavex Life Sciences made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4414 holding.
- David Shaw first reported a position in Anavex Life Sciences in Q2 2016 and has held it in 23 quarters since.
- David Shaw's Anavex Life Sciences position peaked at $3.81M in Q1 2022.
- 177 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.